ERBB2 and breast carcinoma: Indeed, the fact that T-DM1 is an approved drug for HER2+ breast cancer and that both VSV and Maraba are undergoing clinical evaluation for solid tumors including breast cancer (NCT02923466, NCT02285816) provides a clear path to clinical translation of this approach.